Cora Sternberg | Meta analysis | Outstanding Scientist Award

Published on by Network Science

Dr. Cora Sternberg | Meta analysis | Outstanding Scientist Award

Weill Cornell Medicine | United States

Author Profiles

Scopus

Orcid ID

Google Scholar

Early Academic Pursuits

Dr. Cora Sternberg’s academic journey reflects her commitment to excellence from the outset. She completed her medical training with distinction and pursued advanced fellowships, including a Research Fellowship in Immunology at the National Institutes of Health (1976–1977). Her early academic roles as Teaching Assistant at Stanford and Mount Sinai, followed by Clinical Instructor at Cornell University, laid the foundation for her lifelong dedication to education and clinical research. Her Phi Beta Kappa distinction from the University of Pennsylvania marked the start of a career dedicated to innovation and leadership in oncology.

Professional Endeavors

Over four decades, Dr. Sternberg has held prestigious academic and clinical leadership roles. She was Chief of Medical Oncology at San Camillo-Forlanini Hospital in Rome and served as Professor at La Sapienza University, shaping Italy’s oncology community. Since 2018, she has been Professor of Medicine and Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine and New York-Presbyterian. She has also served as a global faculty member at Temple University, Tufts University, and European institutions.

Contributions and Research Focus

Dr. Sternberg has pioneered groundbreaking research in prostate cancer, bladder cancer, and renal cell carcinoma. She was instrumental in developing practice-changing therapies such as abiraterone, enzalutamide, and darolutamide, significantly improving survival outcomes for prostate cancer patients. Her work in urothelial cancer led to the establishment of M-VAC chemotherapy and global adoption of immunotherapy protocols. She also contributed to the development of pazopanib and other targeted therapies in renal cell carcinoma. Recently, she has expanded her research focus to artificial intelligence in oncology, spearheading initiatives to integrate AI into therapeutic decision-making.

Impact and Influence

With over 546 publications, six textbooks, and more than 45,200 citations, Dr. Sternberg ranks among the World’s Top 2% Scientists (Stanford University) and the top 5% in the Doximity community for citations. She has delivered more than 835 lectures worldwide, influencing clinical practice, policy, and guidelines in oncology. Her leadership roles in international organizations such as ASCO, ESMO, ECCO, and EORTC demonstrate her far-reaching influence.

Academic Citations

Dr. Sternberg’s research impact is widely recognized. Her publications in high-impact journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology have shaped global treatment standards. Her works are consistently cited in clinical guidelines, trial protocols, and oncology education, affirming her stature as a thought leader in medical oncology.

Legacy and Future Contributions

Dr. Sternberg’s legacy lies not only in transformative research but also in mentorship. She has nurtured generations of oncologists, fostering innovation and translational research. Currently, she co-leads the Career Development Program in the Bladder SPORE initiative, ensuring the pipeline of future oncology leaders. Her pioneering role in AI in oncology positions her to continue shaping the future of precision medicine, bridging clinical care with technological innovation.

Conclusion

Dr. Cora Sternberg exemplifies the qualities of an Outstanding Scientist—visionary leadership, transformative research, global influence, and unwavering dedication to advancing oncology. Her lifelong contributions to clinical practice, groundbreaking research, academic mentorship, and adoption of emerging technologies ensure her lasting impact on the medical community and future generations of scientists.

Notable Publications

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100" 

  • Author: homas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Cancers
  • Year: 2025

"The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making" 

  • Author: Olivier Elemento; Sean Khozin; Cora N. Sternberg
  • Journal: NEJM AI
  • Year: 2025

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100" 

  • Author: Thomas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Preprint
  • Year: 2025

"Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591" 

  • Author: Scott T. Tagawa; Charlene Thomas; A. Oliver Sartor; Michael Sun; Judith Stangl-Kremser; Mahelia Bissassar; Shankar Vallabhajosula; Sandra Huicochea Castellanos; Jones T. Nauseef; Cora N. Sternberg et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2024

"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial" 

  • Author: Maha Hussain; Bertrand Tombal; Fred Saad; Karim Fizazi; Cora N. Sternberg; E. David Crawford; Neal Shore; Evgeny Kopyltsov; Arash Rezazadeh Kalebasty; Martin Bögemann et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2023

 

 

Yuan Zhang | Pharmaceutical Sciences | Best Researcher Award

Published on by Network Science

Prof. Yuan Zhang | Pharmaceutical Sciences | Best Researcher Award

Deputy Director at South China University of Technology, China📖

Dr. Yuan Zhang is a distinguished professor at South China University of Technology, where he serves in the School of Biomedical Sciences and Engineering at the Guangzhou International Campus. Additionally, he contributes to the National Engineering Research Center for Tissue Restoration and Reconstruction. With a career marked by groundbreaking research in pharmaceutical sciences and nanotechnology, Dr. Zhang has established himself as a leading figure in drug delivery systems and cancer research.

Profile

Google Scholar Profile

Education Background🎓

Dr. Zhang completed his postdoctoral research fellowship at the Massachusetts Institute of Technology (MIT) from 2013 to 2016, under the mentorship of Prof. Darrell J. Irvine, a National Academy of Medicine member and Howard Hughes Medical Institute (HHMI) investigator. He earned his Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in 2013, where he specialized in molecular pharmaceutics and nanotechnology. Before this, he received his M.S. in Pharmaceutical Sciences from Peking University in 2009, guided by Prof. Qiang Zhang, a member of the Chinese Academy of Engineering. Dr. Zhang also holds dual bachelor’s degrees in Pharmaceutical Sciences and Economics from Peking University.

Professional Experience🌱

Dr. Zhang began his academic career as an Assistant Professor at the University of Rhode Island from 2016 to 2019, where he excelled in advancing biomedical and pharmaceutical sciences. Since 2019, he has been a professor at South China University of Technology, contributing significantly to research in tissue restoration and reconstruction while mentoring the next generation of scientists.

Research Interests🔬

Dr. Zhang’s research focuses on nanotechnology for drug delivery, tissue engineering, and cancer therapy. He explores innovative approaches to enhance the efficacy and precision of drug delivery systems, emphasizing translational research to improve patient outcomes. His contributions to molecular pharmaceutics and tissue restoration have opened new avenues in biomedical sciences, particularly in regenerative medicine and targeted therapeutics.

Author Metrics

Dr. Zhang’s research has led to numerous high-impact publications in leading journals, reflecting his expertise in drug delivery systems, nanotechnology, and cancer therapeutics. His work is widely cited, underscoring his influence and thought leadership in pharmaceutical sciences.

Publications Top Notes 📄

1. In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles

Authors: Y. Zhang, A. Satterlee, L. Huang
Journal: Molecular Therapy, 2012, 20(7), pp. 1298–1304
Citations: 470
Summary:
This paper discusses the challenges of in vivo gene delivery using nonviral vectors, emphasizing strategies to overcome barriers such as stability, targeting efficiency, and cellular uptake. The study highlights advancements in nanotechnology and biomaterials that enhance the potential of nonviral vectors for clinical applications in gene therapy.

2. Delivering Safer Immunotherapies for Cancer

Authors: L. Milling, Y. Zhang, D.J. Irvine
Journal: Advanced Drug Delivery Reviews, 2017, 114, pp. 79–101
Citations: 305
Summary:
The paper reviews recent developments in cancer immunotherapies, focusing on minimizing systemic toxicity while enhancing efficacy. It explores strategies such as targeted delivery systems, immune checkpoint inhibitors, and nanocarriers to ensure safer and more effective immunotherapy solutions.

3. Nanoparticle Anchoring Targets Immune Agonists to Tumors Enabling Anti-Cancer Immunity Without Systemic Toxicity

Authors: Y. Zhang, N. Li, H. Suh, D.J. Irvine
Journal: Nature Communications, 2018, 9(1), Article 6
Citations: 215
Summary:
This study introduces a novel nanoparticle system for targeting immune agonists directly to tumors, thereby inducing a potent anti-cancer immune response. The method reduces systemic toxicity and enhances the therapeutic index of immune-based treatments, representing a breakthrough in cancer immunotherapy.

4. Biomimetic Diselenide‐Bridged Mesoporous Organosilica Nanoparticles as an X‐Ray‐Responsive Biodegradable Carrier for Chemo‐Immunotherapy

Authors: D. Shao, F. Zhang, F. Chen, X. Zheng, H. Hu, C. Yang, Z. Tu, Z. Wang, Y. Zhang, et al.
Journal: Advanced Materials, 2020, 32(50), Article 2004385
Citations: 199
Summary:
The paper presents innovative mesoporous organosilica nanoparticles with diselenide bridges for X-ray-triggered chemo-immunotherapy. These nanoparticles are biodegradable, providing a controlled drug release system that combines chemotherapy and immunotherapy for enhanced anti-cancer efficacy.

5. Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy

Authors: S. Guo, Y. Wang, L. Miao, Z. Xu, C.M. Lin, Y. Zhang, L. Huang
Journal: ACS Nano, 2013, 7(11), pp. 9896–9904
Citations: 145
Summary:
This research develops lipid-coated cisplatin nanoparticles that induce a “neighboring effect,” enhancing anticancer efficacy. The study demonstrates the nanoparticles’ ability to selectively target cancer cells, improve drug delivery, and minimize off-target toxicity, making them a promising candidate for advanced chemotherapy.

Conclusion

Dr. Yuan Zhang exemplifies the qualities of an outstanding researcher, with groundbreaking contributions to pharmaceutical sciences and nanotechnology. His work has significantly advanced the fields of drug delivery, cancer therapy, and tissue restoration, earning him high citation metrics and global recognition. By focusing more on translational research, interdisciplinary collaborations, and public engagement, Dr. Zhang could further amplify the real-world impact of his innovations.

Given his achievements, leadership roles, and potential for future contributions, Dr. Zhang is a highly suitable candidate for the Best Researcher Award, making him a deserving recipient of this prestigious honor.